Breaking News Instant updates and real-time market news.

LPCN

Lipocine

$4.00

0.07 (1.78%)

08:20
09/21/17
09/21
08:20
09/21/17
08:20

Lipocine announces motions decision by USPTO

Lipocine announced that the Patent Trial and Appeal Board, or PTAB, of the United States Patent and Trademark Office issued a Motions Decision based on each party's motions in the interference case, Patent Interference No. 106,045, between Clarus Therapeutics U.S. Patent No. 8,828,428, and Lipocine, U.S. Patent Application No. 14/713,692. The PTAB granted Lipocine's motion to deny Clarus' previously accorded priority date for the '428 Patent. Therefore, Clarus has a new priority date of April 16, 2014 for the Clarus '428 patent. The PTAB also granted Clarus' motion to deny Lipocine's accorded priority date. Therefore, Lipocine's has an accorded priority date of May 15, 2015 for the Lipocine '692 Application. As a consequence of this decision, the PTAB has redeclared the interference and named Clarus as the senior party and Lipocine as the junior party. All other motions were denied. A conference call with the PTAB is scheduled for October 4, 2017 to discuss the next steps, including priority schedule.

  • 26

    Sep

LPCN Lipocine
$4.00

0.07 (1.78%)

10/11/16
ADAM
10/11/16
NO CHANGE
Target $15
ADAM
Buy
Lipocine price target raised to $15 from $6 at Canaccord
Canaccord analyst John Newman raised his price target on Lipocine to $15 from $6 as he believes its oral testosterone product has better safety and convenience versus currently marketed gels and injectables. The analyst sees rapid market share gains and a 20% market share by 2024. Newman reiterated his Buy rating on Lipocine shares.
12/20/16
ADAM
12/20/16
INITIATION
Target $15
ADAM
Buy
Lipocine assumed with a Buy at Canaccord
Canaccord analyst Dewey Steadman assumed Lipocine with Buy and $15 price target citing its status as one of the leading companies developing oral testosterone replacement therapies to treat hypogonadism.
02/21/17
ROTH
02/21/17
NO CHANGE
Target $38
ROTH
Buy
Lipocine price target raised to $38 from $30 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Lipocine to $38 from $30 following clarity on LPCN-1107's pivotal trial design. The analyst reiterates a Buy rating on the shares.
06/20/17
ADAM
06/20/17
NO CHANGE
Target $11
ADAM
Buy
Lipocine data sets path toward FDA submission, says Canaccord
Canaccord analyst Dewey Steadman noted Lipocine reported positive top-line data for its dosing validation and dosing flexibility studies, which were required for the resubmission of its oral testosterone NDA. The analyst sees a resubmission in Q3 and believes the company has sufficient capital to meet near-term needs while the company plans to partner the drug. Steadman reiterated his Buy rating and raised his price target to $11 from $10 on Lipocine shares.

TODAY'S FREE FLY STORIES

BHGE

Baker Hughes

$27.48

1.04 (3.93%)

12:00
02/21/18
02/21
12:00
02/21/18
12:00
Options
Baker Hughes calls active as shares rally »

Baker Hughes calls active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

12:00
02/21/18
02/21
12:00
02/21/18
12:00
General news
FOMC minutes preview: »

FOMC minutes preview: the…

CPB

Campbell Soup

$45.10

-0.985 (-2.14%)

, LNCE

Snyder's-Lance

$50.00

0.05 (0.10%)

11:55
02/21/18
02/21
11:55
02/21/18
11:55
Hot Stocks
Campbell expects $170M in cost synergies from Snyder's-Lance deal by FY22 »

CFO Anthony DiSilvestro…

CPB

Campbell Soup

$45.10

-0.985 (-2.14%)

LNCE

Snyder's-Lance

$50.00

0.05 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Apr

  • 30

    May

HBAN

Huntington Bancshares

$15.90

0.07 (0.44%)

11:50
02/21/18
02/21
11:50
02/21/18
11:50
Options
Call buyers in Huntington Bancshares »

Call buyers in Huntington…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

11:50
02/21/18
02/21
11:50
02/21/18
11:50
General news
Treasury $15 B 2-year FRN reopening was weak »

Treasury $15 B 2-year FRN…

C

Citi

$77.50

1.0399 (1.36%)

11:47
02/21/18
02/21
11:47
02/21/18
11:47
Periodicals
Citi creates new position to supervise EMEA commodities banking, FT says »

According to the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 06

    Mar

  • 07

    Mar

  • 30

    May

XLI

Industrial Select Sector SPDR

$77.42

0.905 (1.18%)

, XLF

Financial Select Sector

$29.21

0.32 (1.11%)

11:43
02/21/18
02/21
11:43
02/21/18
11:43
Technical Analysis
Technical Take: S&P 500 hits session highs at midday »

At time of writing the…

XLI

Industrial Select Sector SPDR

$77.42

0.905 (1.18%)

XLF

Financial Select Sector

$29.21

0.32 (1.11%)

XLB

S&P Select Materials SPDR

$60.73

0.52 (0.86%)

XLK

Technology Select Sector SPDR

$67.79

0.55 (0.82%)

XLRE

Real Estate SPDR

$30.23

-0.145 (-0.48%)

XLP

Consumer Staples Sector SPDR

$54.16

-0.18 (-0.33%)

SPY

SPDR S&P 500 ETF Trust

$273.35

1.945 (0.72%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.31

0.3 (0.83%)

, BIIB

Biogen

$287.45

-4.42 (-1.51%)

11:43
02/21/18
02/21
11:43
02/21/18
11:43
Periodicals
Breaking Periodicals news story on Pfizer, Biogen, Roche »

Pfizer loses IPR…

PFE

Pfizer

$36.31

0.3 (0.83%)

BIIB

Biogen

$287.45

-4.42 (-1.51%)

RHHBY

Roche

$29.77

-0.53 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 08

    Mar

  • 08

    Mar

  • 04

    Apr

  • 30

    May

SLCA

U.S. Silica

$26.56

-4.195 (-13.64%)

11:40
02/21/18
02/21
11:40
02/21/18
11:40
Options
Buy the dip call activity in Silica Holdings as shares tumble on earnings »

Buy the dip call activity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 30

    May

CPB

Campbell Soup

$45.44

-0.64 (-1.39%)

, LNCE

Snyder's-Lance

$50.00

0.05 (0.10%)

11:36
02/21/18
02/21
11:36
02/21/18
11:36
Hot Stocks
Campbell expects Snyder's-Lance deal to deliver 'significant' cost synergies »

Says Snyder's-Lance…

CPB

Campbell Soup

$45.44

-0.64 (-1.39%)

LNCE

Snyder's-Lance

$50.00

0.05 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Apr

  • 30

    May

11:36
02/21/18
02/21
11:36
02/21/18
11:36
General news
2-Yr FRN Note Auction Bid/Cover data reported »

2-Yr FRN Note Auction…

11:36
02/21/18
02/21
11:36
02/21/18
11:36
General news
2-Yr FRN Note Auction Total Amount data reported »

2-Yr FRN Note Auction…

PCRX

Pacira

$31.25

1.1 (3.65%)

11:36
02/21/18
02/21
11:36
02/21/18
11:36
Recommendations
Pacira analyst commentary  »

Pacira Q4 sales momentum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Apr

AIDIF

Air Canada

11:35
02/21/18
02/21
11:35
02/21/18
11:35
Conference/Events
Air Canada management to meet with RBC Capital »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:30
02/21/18
02/21
11:30
02/21/18
11:30
Options
25K Alerian MLP Mar 9th 10.5 puts trade for 20c on ISE »

25K Alerian MLP Mar 9th…

CPB

Campbell Soup

$45.38

-0.7 (-1.52%)

11:30
02/21/18
02/21
11:30
02/21/18
11:30
Hot Stocks
Campbell Soup says goal is to become leading health and well-being food company »

President and CEO Denise…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Apr

  • 30

    May

PERY

Perry Ellis

$26.32

-0.52 (-1.94%)

11:28
02/21/18
02/21
11:28
02/21/18
11:28
Hot Stocks
Perry Ellis announces mens underwear, loungewear license in South Korea »

Earlier today, Perry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBL

Noble Energy

$29.48

0.36 (1.24%)

11:27
02/21/18
02/21
11:27
02/21/18
11:27
Recommendations
Noble Energy analyst commentary  »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

DVN

Devon Energy

$32.86

-1.79 (-5.17%)

11:26
02/21/18
02/21
11:26
02/21/18
11:26
Hot Stocks
Devon Energy CEO confident that investor returns will increase in FY18 »

Devon Energy CEO David…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 28

    Feb

T

AT&T

$36.92

0.15 (0.41%)

, TWX

Time Warner

$95.26

0.19 (0.20%)

11:24
02/21/18
02/21
11:24
02/21/18
11:24
Conference/Events
FBN Securities media analyst to hold an analyst/industry conference call »

Media Analyst Research…

T

AT&T

$36.92

0.15 (0.41%)

TWX

Time Warner

$95.26

0.19 (0.20%)

DIS

Disney

$106.30

0.32 (0.30%)

FOX

21st Century Fox

$36.61

-0.43 (-1.16%)

SNI

Scripps Networks

$88.16

0.35 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 23

    Apr

DIS

Disney

$106.34

0.36 (0.34%)

11:23
02/21/18
02/21
11:23
02/21/18
11:23
Periodicals
Producer of new 'Frozen' musical accused of workplace harassment, WSJ says »

Tom Schumacher, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 01

    Mar

FB

Facebook

$176.01

-1.35 (-0.76%)

, TWTR

Twitter

$32.80

-0.04 (-0.12%)

11:22
02/21/18
02/21
11:22
02/21/18
11:22
Conference/Events
FBN Securities digital media analysts to hold a luncheon »

Digital Media Analysts…

FB

Facebook

$176.01

-1.35 (-0.76%)

TWTR

Twitter

$32.80

-0.04 (-0.12%)

GOOG

Alphabet

$1,102.46

7.66 (0.70%)

GOOGL

Alphabet Class A

$1,103.59

8.09 (0.74%)

AABA

Altaba

$74.59

1.08 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 07

    Mar

  • 18

    Mar

RF

Regions Financial

$19.77

0.37 (1.91%)

11:20
02/21/18
02/21
11:20
02/21/18
11:20
Options
Notable call buying in Regions Financial as shares move higher »

Notable call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
02/21/18
02/21
11:17
02/21/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
02/21/18
02/21
11:16
02/21/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.